Gene therapy in ophthalmology involves introducing genetic material into cells of eye to treat inherited retinal diseases. It holds potential to treat many blinding conditions such as age-related macular degeneration, retinitis pigmentosa and Leber congenital amaurosis that currently have no cure. Gene therapy uses viruses to deliver a normal copy of the faulty gene into retinal cells, allowing them to function normally. This methodology can potentially reverse vision loss and restore sight in patients suffering from inherited retinal diseases.
The gene therapy in ophthalmology market is estimated to be valued at USD 1.2 Bn in 2024 and is expected to reach USD 5.8 Bn by 2031, growing at a compound annual growth rate (CAGR) of 25.2% from 2024 to 2031.
Key Takeaways
Key players operating in the Gene Therapy in Ophthalmology are Johnson & Johnson Innovative Medicine, MeiraGTx, Beacon Therapeutics, Nanoscope Therapeutics, GenSight Biologics. These players are investing significantly in R&D to develop innovative products in clinical pipeline.
The market is witnessing growing demand for Gene Therapy in Ophthalmology Market due to increasing incidence of retinal diseases worldwide and rising focus on precision medicine. As per statistics, inherited retinal diseases affect over 5 million people globally and is a leading cause of blindness in working-age individuals.
Advancements in gene delivery vector technology, gene editing tools and better understanding of retinal cell biology are contributing to promising clinical outcomes of ongoing gene therapy trials. Recent approvals for voretigene neparvovec-rzyl and development of second-generation therapies hold potential to transform treatment landscape of inherited retinal diseases.
Market Trends
Individualized gene therapies - With advancements in gene editing tools, next generation gene therapies are being developed that can target specific genetic mutations causing retinal disease. This paradigm shift towards precision medicine will drive the market growth.
Oligonucleotide therapies - Antisense oligonucleotides that can modify RNA are emerging as alternative to gene replacement therapies. Drugs like Luxturna were approved using this approach are gaining popularity.
Market Opportunities
Untapped emerging markets - Gene therapy trials are heavily concentrated in developed nations. Emerging countries in Asia Pacific and Latin America present significant market opportunities owing to growing disease burden and improving access to novel treatments.
Combination therapies - Combining gene therapy with assistive devices, drugs or other modalities holds potential to maximize therapeutic benefits in difficult to treat retinal conditions. Market players are exploring such combination product development opportunities.
Gene Therapy in Ophthalmology Market: Impact of COVID-19
The COVID-19 pandemic has significantly impacted the growth of the gene therapy in ophthalmology market globally. During the initial outbreak, several clinical trials were halted or postponed due to travel restrictions and social distancing norms. This led to delays in new product developments and innovations. However, telemedicine emerged as a new opportunity during this period to continue patient consultations and care. Researchers also focused on understanding the impact of COVID-19 virus on ocular health.
As restrictions ease now, clinical trials have resumed with safety protocols. But supply chain disruptions continue to pose challenges. The demand for treatments of posterior segment eye diseases is expected to grow post-pandemic as the prevalence of these conditions remains high. Companies are investing in virtual collaborations and partnerships to mitigate delays. While short-term growth was hampered, the long-term need for gene therapies in retinal diseases remains strong given limited alternatives. The market is anticipated to bounce back gradually as research advances.
Gene Therapy in Ophthalmology Market: Geographical Concentration
In terms of value, North America dominates the global gene therapy in ophthalmology market currently due to favourable regulations, rising blindness rates, growing geriatric population and availability of advanced healthcare facilities. The US accounts for the major share within the region supported by rising genetic research funding and presence of key market players.
Europe holds the second largest regional market share with major markets being Germany, France and the United Kingdom. However, Asia Pacific is emerging as the fastest growing regional market supported by increasing healthcare investments, expanding ophthalmic patient pool and rising medical tourism in countries like India, China and South Korea. Improving research infrastructure and growing clinical trials in retinal disorders are further boosting the Asia Pacific gene therapy in ophthalmology market.
Gene Therapy in Ophthalmology Market: Fastest Growing Region
Asia Pacific region is poised to exhibit the highest growth in the global gene therapy in ophthalmology market during forecast period from 2024 to 2031. This can be attributed to substantial improvements in healthcare facilities, rapid economic developments, growing medical tourism and rising government initiatives to strengthen research infrastructure across major Asian countries. As per estimates, the Asia Pacific market size will demonstrate over 28% CAGR and surpass a value of USD 500 Million by 2031.
Especially countries like China, India, South Korea and Taiwan will drive the high growth as they have large geriatric population bases susceptible to retinal disorders coupled with increasing healthcare expenditures. Emergence of local biopharmaceutical companies and expansion of international players will further support market growth in Asia Pacific. Improving regulatory guidelines and focus on clinical trials will additionally propel the gene therapy in ophthalmology market demand in this region. Affordability and accessibility of treatment options will remain high growth influencers.
Get More Insights - Gene Therapy in Ophthalmology Market
Explore More Related Articles - Sacroiliac Joint Fusion: A Guide to this Life-Changing Back Procedure
Author Bio:
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)
